Antengene presents preclinical data for ATG-125 bispecific ADC at AACR 2026

• Antengene disclosed preclinical results from three oncology programs in poster presentations at AACR 2026.
• ATG-125, a bispecific antibody-drug conjugate, showed antitumor activity in multiple models, supporting further development in solid tumors.
• ATG-106, a T cell engager, produced tumor regressions in ovarian and kidney cancer models, with findings consistent with a manageable cytokine-related safety profile.
• ATG-112, another T cell engager, demonstrated broad antitumor effects across ALPP/G-positive tumor models, with minimal cytokine release in preclinical testing.
• Poster sessions are scheduled for April 20-21, 2026, positioning Antengene pipeline assets for potential clinical advancement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604172030PR_NEWS_USPR_____CN36113) on April 18, 2026, and is solely responsible for the information contained therein.